This is an audio transcript of the FT News Briefing podcast episode: ‘Big Pharma markets left in a ‘patent cliff’-hanger’ ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...

Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion last year. Keytruda may also face “ price setting ” from the Inflation ...

Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...

Merck says it will acquire London-based Verona Pharma for about US$10bil, gaining a promising respiratory treatment as it ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug ...

Merck's animal health division received Food and Drug Administration approval for its once-yearly injectable flea-and-tick treatment for dogs. Merck Animal Health said Thursday it expects its Bravecto ...